Pathology in the UK Bowel Cancer Screening Programmes Frank Carey (Dundee)

Slides:



Advertisements
Similar presentations
Bowel Cancer screening programme The Facts Third most common Cancer in the UK. The Second most common cause of cancer deaths in the UK (approx 16,100.
Advertisements

Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Spotlight on Colorectal Cancer Screening 1 1. Home Screening for Colon Cancer
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
Nicola Barnstaple Programme Manager. Key challenges in Scotland Increasing cancer incidence – predicted 35,000 cases per year in 2020 Ageing population.
Bowel Cancer and Screening Dr M T Hendrickse Clinical Director/ Lead Colonoscopist Lancashire Bowel Screening Centre Blackpool Fylde and Wyre NHS Hospitals.
DR Jameel Tariq Miro.  Lifetime incidence 5%  90% of cases occur after age 50  One-third of patients with colorectal cancer die from the disease 
Colorectal cancer: How do we approach health disparities? Marta L. Davila, MD, FASGE University of Texas MD Anderson Cancer Center.
Bowel Cancer and Screening
Joint Hospital Surgical Grand Round 19 June 2004.
Update on Colorectal Cancer Screening Tests Source: Levin Bernard et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous.
Sharp L, Tilson L, Whyte S, Ó Céilleachair A
Wilson and Jungner Criteria for Screening 1968
Maureen Sayer Health Improvement Practitioner Cheshire and Merseyside Bowel Cancer Screening Programme.
Reporting and Management of Early stage Colorectal Cancer Frank Carey Dundee.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Bowel Cancer Screening Programme Cheshire and Merseyside NHS North West.
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
General Medicine Subspecialty Conference Colon Cancer Screening General Medicine Subspecialty Conference Colon Cancer Screening Selim Krim, MD Assistant.
The Tayside Experience The Long Road To Implementation Peter Rice, Consultant Psychiatrist, NHS Tayside Alcohol Problems Service.
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
Colonoscopy; Surveillance Indications
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Results and cost of a population-based biennial faecal occult blood colorectal cancer screening program Bernard DENIS, Philippe PERRIN, Jean François VIES,
Colorectal Screening NZ Bowel Screening Pilot. WHO Screening criteria  Impt Health condition  Identifiable Latent or early stage  Understand natural.
Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.
COMPARING YIELD AND COST OF FOBT AND FS IN AN AVERAGE RISK POPULATION: RESULTS AFTER 2 SCREENING ROUNDS N.Segnan MD, Ms Epi Center for Cancer Prevention.
Population Screening for Colorectal Cancer - update of evidences
An Evidence Based Approach to Colorectal Cancer Screening J. C. Ryan, M.D. Associate Professor of Medicine UCSF and SF VAMC 9/22/2014.
SETTING UP THE SERVICE BY LYNN TOBIN. HOW DID WE GET HERE? ABUNDENCE OF EVIDENCE PROVIDING JUSTIFICATION FOR BOWEL CANCER SCREENING.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
PREPARED BY National Bowel Screening Programme Meeting 19 August 2015.
PREPARED BY Colorectal Cancer Programme Screening for Colorectal Cancer A/P Susan Parry, Gastroenterologist, CD MOH Bowel Cancer Programme.
Perspectives from the Waitemata Bowel Screening Pilot team -The Endoscopic view Paul Frankish Lead Endoscopist.
Brian Cox Research Associate Professor: Cancer epidemiology and screening University of Otago Hugh Adam Cancer Epidemiology Unit Department of Preventive.
Screening for Colorectal Cancer (CRC) Nov, 2007 A Aljebreen, FRCPC Division of Gastroenterology KKUH, Riyadh.
Cheshire & Merseyside Bowel Cancer Screening Programme April 2008.
Colorectal Cancer Screening Colorectal Cancer Screening VT SGNA Conference VT SGNA Conference October 24, 2015 October 24, 2015 Lynn Butterly, MD Lynn.
NHSBCSP - guidelines Phil Quirke. Why guidelines To meet the needs of the programme To improve outcomes To increase the knowledge base and evolve pathology.
National Oesophago–Gastric Cancer Audit  This slide set is designed to ◦Summarise the main audit findings for presentation at local MDT meetings.
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
Cheshire & Merseyside Bowel Cancer Screening Programme April 2008.
Colorectal Cancer Screening Implementation of a public health programme An Expert Group on Colorectal Cancer Screening Cancer Society of Finland, Finnish.
D EPARTMENT of F AMILY M EDICINE Colorectal Cancer Screening: Update on Guidelines and Projects Barcey T. Levy, PhD, MD Professor, Department of Family.
First results of a pilot population-based faecal occult blood colorectal cancer screening program B. DENIS, P. PERRIN, J.F. EBELIN, P. WEBER, E. KALTENBACH,
Insert name of presentation on Master Slide Bowel Screening in Welsh Prisons Hayley Heard Head of Programme.
A Pharmacy Based Bowel Cancer Screening Program. Did You Know? Bowel cancer kills more Australians each year than breast or prostate cancer (AIHW 2012.
FIT Programme (Faecal Immunohistochemical Test)
Cancer prevention and early detection
بسم الله الرحمن الرحيم.
Colorectal Cancer Screening Guidelines
BOWEL SCOPE SCREENING Dorset BCSP
National Oesophago–Gastric Cancer Audit 2015.
27th Annual Winter CME Conference
Bowel cancer screening update GP education event 28 Nov 2017
The Bowel Screening Programme in Wales
Consultant Respiratory Physician Professor of Primary Care Oncology
BOWEL CANCER SCREENING 11/7/18
Bowel Screening in Wales
Ruggli M.1), Stebler D.1), Besancon L.1), Vaucher F.1)
Colorectal Cancer Cancer Alliance Work
BOWEL CANCER SCREENING IN LEWISHAM
FIT for symptomatic patients
Louise Newton & Cathy Corcoran
Colorectal 2 week wait pathways and “Getting FIT”
Faecal Immunochemistry Test - qFIT
Presentation transcript:

Pathology in the UK Bowel Cancer Screening Programmes Frank Carey (Dundee)

Screening for Large Bowel Cancer Faecal occult blood (FOB) –Guaiac –Immunological Sigmoidoscopy Colonoscopy CT Colography

FOB Screening for colorectal Cancer The research The pilot The programmes Pathology

The Research Population screening with FOB + colonoscopy reduces disease-specific mortality from colorectal cancer –Mandel et al N Engl J Med 1993 –Kronborg et al Lancet 1996 –Hardcastle et al Lancet 1996

Meta-Analysis of FOBT Trials Overall relative risk of death –0.84 (CI ) –16% reduction in deaths Adjusted for uptake –0.77 (CI ) –23% reduction in deaths (Towler et al 1998)

Effect of Screening on Colorectal Cancer Incidence Control group Screened groups

UK Pilots (2000 onwards) Aim: to test feasibility of screening in “real life” NHS –Coventry and Warwickshire –Fife, Grampian and Tayside (each with approx. 1m pop.)

Operation of Pilots Central call/recall, administration, helpline Postal delivery of FOB kits Analysis in newly constructed labs (run by Biochemistry) Minimum primary care involvement Screening Group (lead clinician, surgery, pathology, biochemistry, nursing, public health, radiology)

Screening Pilot Start date:29 March 2000 Postal delivery of test kit from Centre One reminder test kit Dietary restriction for weak positive Nurse interview Colonoscopy

UK First Round Screening Algorithm Guaiac FOBT WP [1-4 spots positive] P [5-6 spots positive] Retest WPN WPP [any spot P] Retest InvestigationWPNP [any spot P] WPNN Repeat tests had dietary restriction

Key Performance Indicators (KPIs) 1.Uptake –overall –by deprivation category –response rate to first invitation –response rate to reminders 2.Time to colonoscopy 3.Proportion of +ves undergoing colonoscopy 4.Colonoscopy completion rate 5.Colonoscopy complication rate –admissions –perforations –bleeding –deaths 6.Positivity rate 7.Cancer Detection Rate 8.Stage at diagnosis (incl. polyp cancers) 9.Adenoma detection rate –overall –high risk 10.PPV –for cancer –for adenoma –for high risk adenoma –for any neoplasia

KPI 1 (Uptake) 1 st round2 nd round3 rd round (provisional) Overall 1 st invite 55% 44% 53% 51% 50%

Age and Sex Uptake, % Age range

Deprivation Category Uptake, % SIMD

KPI 1 (Uptake) 2 nd round3 rd round (provisional) Non-responders in previous round Responders in previous round 14% 85% 13% 87%

KPI 2 (Time to colonoscopy) 1 st round2 nd round3 rd round (provisional) 2 weeks 4 weeks 6 weeks 20% 40% 65% 26% 61% 76% 50% 84% 97%

KPI 3 (Proportion of FOBT positive individuals undergoing colonoscopy) 1 st round2 nd round 3 rd round 85.5% 85.9% 87.3% (provisional)

KPI 4 (Colonoscopy completion rate) 1 st round2 nd round 3 rd round 88.0% 90.9% 94.7% (provisional)

KPI 5 (Colonoscopy complication rates) 1 st round2 nd round3 rd round (provisional) Admissions Deaths 0.3% 0 0.4% 0 0.4% 0

KPI 6 (FOB positivity) 1 st round2 nd round 3 rd round 2.1% 1.9% 1.0% (provisional)

KPI 7 (Cancer detection rate /1000 screened) 1 st round2 nd round 3 rd round (provisional)

KPI 8 (Stage at diagnosis) Stage 1 st round2 nd round A 49.2% B 20.3% C1 18.1% C2 2.8% D 7.1% Polyp 17.8% Unknown 2.5% 38.4% 25.8% 20.5% 3.7% 1.9% 12.6% 10.0%

Stage Distribution of Symptomatic Colorectal Cancer A8% D25% B33% C34%

Stage Distribution of Screen -Detected Cancers True A 26% 48% C26% Polyp Cancers 22% D1% B25%

Meaning of FOBT + Initial positivity 2%. Of these; –40% have neoplasia (30% adenoma 10% cancer) –10% have something else (eg inflammatory bowel disease)

Colonoscopy Activity at Ninewells Hospital (by quarter) Start of screening

Workload change in Ninewells pathology Pre- FOB Post- FOB Adenomas (+ 23%) Adenocarcinoma (+9.7%) *Overall effect on colorectal specimen number is not large

First NHS screening colonoscopy Asymptomatic solitary sigmoid polyp (11mm) Complete excision of moderately differentiated adenocarcinoma (no lymphatic/vascular invasion)

All Cancers – Screened Health Boards 37% 54% 48% 42% P<0.01 * Screening will save 150 lives per year in Scotland

Cancers in a screened population Screen detected Interval cancers (about half of all cancers in screened population in Nottingham) –After negative FOB –After positive FOB/negative colonoscopy Cancers in those refusing FOB screening

Polyps bleed…….. About 2900 polyps were removed in the Scottish Pilot 1 st round Vast majority hyperplastic polyps or adenomas

Adenomas in Screening Adenomas much more common than cancers Adenomas are the precursors of most cancers Adenomas (even when removed) are a marker of cancer risk The programme is almost as much about adenomas as cancer

KPI 9 (Adenoma detection rate /1000 screened) 1 st round2 nd round3 rd round (provisional) Adenomas HR Adenomas

KPI 10 (PPV) 1 st round2 nd round3 rd round (provisional) Cancer Adenoma HR Adenoma All Neoplasia 12.0% 36.5% 3.3% 48.5% 6.8% 29.5% 2.9% 36.3% 8.5% 30.1% 3.0% 38.6%

Interval Cancers (All cancers diagnosed in the population who responded to the 1 st round screening invitation within 2 years of their FOBT result) Number% Screen-detected True Interval Missed on colonoscopy Miscellaneous Total606100

Adenoma Follow-up Scheme Low risk 1 or 2 small adenomas <10mm Intermediate risk 3 or 4 adenomas or, at least one >10mm High risk (1) 5 or more adenomas or, At least three >10mm Surveillance by FOBt * (or exceptionally colonoscopy at 5 years) Colonoscopy at 3 yearsColonoscopy at 1 year ACB Findings at follow up: No adenomas B No adenomas x 2 cease follow up Intermediate or high risk B or C Findings at follow up: No adenomas B Intermediate or low risk B High risk C Low risk adenomas: Patients in whom one or two small tubular adenomas are removed are at no significant additional risk of developing colonic cancer, and may have a reduced risk of developing rectal cancer, when compared with the unexamined population. Surveillance by FOB testing within the screening programme is recommended. Polyp cancers- Histology should be reviewed and further management discussed at an appropriate Multi-Disciplinary Team meeting. If surgical resection is not indicated then the patient should be followed in the high risk category High risk (2) Large sessile adenoma removed piecemeal D Check eradication at three months ?re-treat D ? needs surgery Inspect at 1 year No adenoma B Notes:

Pathological measurement of polyp size

Bowel Screening Programmes England – initially years (pilot was 50-69) Scotland – years* Wales – in planning stages N. Ireland – no immediate plans *Peak incidence is approximately 72 years

Programme Organisation England: –Screening hubs provide call/recall, FOB laboratory, facilitate polyp surveillance –Screening centres provide nurse clinics, colonoscopy, pathology, cancer treatment Scotland: –Central FOB laboratory, call/recall centre in Dundee. All other activity devolved to local NHS Boards

Funding New funding available in England (including allocation for pathology) Funding contingent on gathering of agreed datasets No additional funding in Scotland

Pathology Make a diagnosis Plan treatment and follow up Collect accurate data Audit of service development Facilitate high quality research

Applied research Effect of programme on mortality Diagnostic accuracy in early cancers Prognosis in screen detected early stage cancer Polyp cancers Interval cancers Cancers in those declining screening Follow-up of adenomas Does adenoma removal reduce the incidence of cancer Resource includes data and tissue (for molecular and immunohistochemical study)

UK Bowel Screening Programs Probably the best database on adenoma and early colorectal cancer in the world A major opportunity

Role of FIT? (Faecal Immunochemical Testing)

FOBt Technology Traditional guaiac tests –Hemoccult, Hema-screen, ColoScreen Sensitive guaiac tests –Hemoccult Sensa, ColoScreen ES Immunochemical tests –InstantView, immunoCARE, Hemosure, Inform, Confirm, Hemascreen Specific

FOBt Technology and Cut- off Values Traditional guaiac tests – μg Hb/g faeces Sensitive guaiac tests –300μg Hb/g faeces Immunochemical tests –20-50μg Hb/g faeces –Variable (e.g. OC Sensor)

gFOB +ve awaiting colonscopy (n=1600) FIT negative in both [N/N] negative in one and positive in the other [N/P] positive in both [P/P] N/N 346 (21.6%) N/P 258 (16.1%) P/P 996 (62.3%)

Positive Guaiac Test (n=1600) %

Neg/Neg Immuno Test (n=346) %

Neg/Pos Immuno Test (n=258) %

Pos/Pos Immuno Test (n=996) % P<0.001

Screening algorithm Guaiac FOBT WP [1-4 spots positive] P [5-6 spots positive] Retest FIT N FIT P Investigation = 30% reduction in colonoscopies = 60% reduction in unnecessary colonoscopies

“Keeping Scottish Pipes in Tune” (Spot the true Scotsman)